DK1600460T3 - Anvendelse af et aktivt stof, der binder sig til CD28, til fremstilling af en farmaceutisk sammensætning til behandling af B-CLL - Google Patents

Anvendelse af et aktivt stof, der binder sig til CD28, til fremstilling af en farmaceutisk sammensætning til behandling af B-CLL

Info

Publication number
DK1600460T3
DK1600460T3 DK04078136T DK04078136T DK1600460T3 DK 1600460 T3 DK1600460 T3 DK 1600460T3 DK 04078136 T DK04078136 T DK 04078136T DK 04078136 T DK04078136 T DK 04078136T DK 1600460 T3 DK1600460 T3 DK 1600460T3
Authority
DK
Denmark
Prior art keywords
cll
preparation
treatment
pharmaceutical composition
active compound
Prior art date
Application number
DK04078136T
Other languages
English (en)
Inventor
Thomas Hanke
Original Assignee
Theramab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramab Llc filed Critical Theramab Llc
Application granted granted Critical
Publication of DK1600460T3 publication Critical patent/DK1600460T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04078136T 2003-11-11 2004-11-11 Anvendelse af et aktivt stof, der binder sig til CD28, til fremstilling af en farmaceutisk sammensætning til behandling af B-CLL DK1600460T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2003152900 DE10352900A1 (de) 2003-11-11 2003-11-11 Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL

Publications (1)

Publication Number Publication Date
DK1600460T3 true DK1600460T3 (da) 2012-11-19

Family

ID=34585025

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04078136T DK1600460T3 (da) 2003-11-11 2004-11-11 Anvendelse af et aktivt stof, der binder sig til CD28, til fremstilling af en farmaceutisk sammensætning til behandling af B-CLL

Country Status (6)

Country Link
US (4) US20060008457A1 (da)
EP (1) EP1600460B1 (da)
DE (1) DE10352900A1 (da)
DK (1) DK1600460T3 (da)
ES (1) ES2391455T3 (da)
PT (1) PT1600460E (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
EP1600164A3 (de) * 2003-09-22 2006-05-17 TeGenero AG Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE10352900A1 (de) * 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
WO2006050949A2 (de) * 2004-11-11 2006-05-18 Tegenero Ag Superagonistische anti-cd28 antikörper
US7585960B2 (en) 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
EP2262838B1 (en) * 2008-03-13 2016-04-13 Biotest AG Agent for treating disease
MX2010010027A (es) * 2008-03-13 2011-05-02 Biotest Ag Agente para tratar enfermedad.
RU2539110C2 (ru) * 2008-03-13 2015-01-10 Биотест Аг Способ лечения аутоиммунного заболевания (варианты)
RU2531548C2 (ru) * 2008-09-29 2014-10-20 Биотест Аг Композиция для лечения заболевания
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
CN115814092B (zh) * 2022-12-20 2024-07-09 中国医学科学院医学生物学研究所 与急性t淋巴细胞白血病治疗相关的靶点cd28及其应用
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19722888A1 (de) * 1997-05-28 1998-12-03 Thomas Prof Dr Huenig Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
ES2392287T3 (es) * 2001-12-04 2012-12-07 Theramab Llc Péptido o proteína que contiene un bucle C'-D de la familia de receptores de la CD28
DE10212108A1 (de) * 2002-03-13 2003-10-02 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE10352900A1 (de) * 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL

Also Published As

Publication number Publication date
US20160017039A1 (en) 2016-01-21
US9119840B2 (en) 2015-09-01
PT1600460E (pt) 2012-10-09
ES2391455T3 (es) 2012-11-26
DE10352900A1 (de) 2005-06-16
EP1600460A1 (de) 2005-11-30
US20070122410A1 (en) 2007-05-31
US20060008457A1 (en) 2006-01-12
EP1600460B1 (de) 2012-08-15
US20130078257A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
DK1730259T3 (da) Fremgangsmåde til fremstilling af en sammensætning omfattende tørrede mikroorganismer
DK1631569T3 (da) Quinuclidinderivater, der binder til muscariniske M3-receptorer
LTPA2017005I1 (lt) Nauji junginiai, kaip opioido receptoriaus moduliatoriai
DK1572874T3 (da) Antistoffer, der immunospecifikt binder til TRAIL receptorer
DK1830956T3 (da) Fremgangsmåde til forberedelse af katalytiske materialer
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1755555T3 (da) Fremgangsmåde til fremstilling af tørpulversammensætninger af glycopyrrolat
AP2006003534A0 (en) Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists.
DK1863812T3 (da) Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler
DK1816935T3 (da) System med kapsel, der har forseglingsmidler
WO2006025979A3 (en) Modulators of nuclear receptors
DK1505974T3 (da) Anvendelse af forbindelser, der er effektive som selektive opiatreceptormodulatorer
BRPI0821301A2 (pt) Composto de aspirinato de isossorbida, composto carregador, composto medicamentoso, composição farmacêutica, e, uso de um composto
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
GEP20115239B (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
DK1546122T3 (da) Fremgangsmåde til fremstilling af valsartan
ATE380166T1 (de) Hydraulisches bindemittel
NO20053762D0 (no) Kondensert furanforbindelse.
ATA6002004A (de) Hydraulisches bindemittel
DK1612200T3 (da) Gødningssammensætning
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
NO20041865L (no) Pressbar sprengstoffkomposisjon
DK1957517T3 (da) Anvendelse af peptider, der binder til TPO-receptor
DK1725223T3 (da) Anvendelse af antagonister til CB1-receptoren til fremstilling af en sammensætning, der er anvendelig til behandling af leversygdomme